Since tumour antigens are generally weakly immunogenic, they often induce a low level of spontaneous immunity or, in other cases, the spontaneous response can lead to tolerance [47] . The molecular precision offered by genebased vaccines, together with the facility to include additional genes to direct and amplify immunity, could lead to an efficient methods to use the immune system against cancer.